Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 8/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 8/20 | 0.33 |
| ▸ | CHRNB4 | P30926 | 7/20 | 0.33 |
| ▸ | CHRNA3 | P32297 | 7/20 | 0.33 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | LPL | P06858 | 1/20 | 0.33 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29951314 | 1.00 | CHRNB2 (0.33) | CHRNB2CHRNA4CHRNB4CHRNA3ENPP2 | |
| SCHEMBL29951776 | 0.78 | ENPP2 (0.41) | ENPP2ALDH1A1 | |
| SCHEMBL16754314 | 0.78 | CYP2A6 (0.36) | CHRNB2CHRNA4CHRNB4CHRNA3CA2 | |
| SCHEMBL3340525 | 0.78 | ENPP2 (0.41) | ENPP2ALDH1A1 | |
| SCHEMBL18895037 | 0.77 | CA2 (0.34) | ENPP2CA2LPLLIPG | |
| SCHEMBL16113231 | 0.75 | CHRNB2 (0.39) | CHRNB2CHRNA4ENPP2CA2LPL | |
| SCHEMBL14121768 | 0.75 | KEAP1 (0.33) | ENPP2 | |
| SCHEMBL29953155 | 0.75 | PIK3CD (0.43) | ENPP2ALDH1A1 | |
| SCHEMBL427156 | 0.75 | CA2 (0.33) | CA2LPLLIPG | |
| SCHEMBL29825823 | 0.75 | CA2 (0.33) | CA2LPLLIPG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120065404-A1 | Process for Preparing Ethyl (s)-2-Ethoxy-4-[N-[1-(2-Piperidinophenyl)-3-Methyl-1-Butyl]Aminocarbonyl Methyl]Benzoate and Use Thereof for the Preparation of Repaglinide | ACTAVIS GROUP PTC HF (IS) | 2012-03-15 | — | — | US | claimed |
| US-8101769-B2 | Chemical intermediate; high purity drug | ACTAVIS GROUP PTC EHF (IE) | 2012-01-24 | — | — | US | claimed |
| US-20100197732-A1 | Repaglinide Substantially Free of Dimer Impurity | ACTAVIS GROUP PTC EHF (IS) | 2010-08-05 | — | — | US | claimed |
| EP-2155706-A2 | REPAGLINIDE SUBSTANTIALLY FREE OF DIMER IMPURITY | Actavis Group PTC EHF (IS) | 2010-02-24 | — | — | EP | claimed |
| EP-2121644-A2 | IMPROVED PROCESS FOR PREPARING ETHYL (S)-2-ETHOXY-4-[N-[1-(2- PIPERIDINOPHENYL)-3-METHYL-1-BUTYL]AMINOCARBONYL METHYL]BENZOATE AND USE THEREOF FOR THE PREPARATION OF REPAGLINIDE | Actavis Group PTC EHF (IS) | 2009-11-25 | — | — | EP | claimed |
| WO-2009004485-A2 | REPAGLINIDE SUBSTANTIALLY FREE OF DIMER IMPURITY | ACTAVIS GROUP PTC EHF (IS) | 2009-01-08 | — | — | WO | claimed |
| US-20080200684-A1 | Process for Preparing Ethyl (s)-2-Ethoxy-4-[N-[1-(2-Piperidinophenyl)-3-Methyl-1-Butyl]Aminocarbonyl Methyl]Benzoate and Use Thereof for the Preparation of Repaglinide | ACTAVIS GROUP PTC HF (IS) | 2008-08-21 | — | — | US | claimed |
| WO-2008099286-A2 | IMPROVED PROCESS FOR PREPARING ETHYL (S)-2-ETHOXY-4-[N-[1-(2- PIPERIDINOPHENYL)-3-METHYL-1-BUTYL]AMINOCARBONYL METHYL]BENZOATE AND USE THEREOF FOR THE PREPARATION OF REPAGLINIDE | ACTAVIS GROUP PTC EHF (US) | 2008-08-21 | — | — | WO | claimed |
| EP-4499630-A1 | BCL-XL INHIBITORS | BeiGene, Ltd. (KY) | 2025-02-05 | — | — | EP | disclosed |
| US-20250034128-A1 | BCL-XL INHIBITORS | BEIGENE, LTD. (KY) | 2025-01-30 | — | — | US | disclosed |
| CN-118974033-A | Bcl-xL inhibitors | 百济神州有限公司 | 2024-11-15 | — | — | CN | disclosed |
| CN-114984003-B | Aromatic sulfonamide derivatives | 拜耳制药股份公司 | 2024-08-27 | — | — | CN | disclosed |
| CN-115054600-B | Aromatic sulfonamide derivatives | 拜耳制药股份公司 | 2024-06-14 | — | — | CN | disclosed |
| WO-2024123967-A1 | SARM1 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | SENYA PHARMACEUTICALS, INC. (US) | 2024-06-13 | — | — | WO | disclosed |
| WO-2010038465-A1 | 8-SUBSTITUTED ISOQUINOLINE DERIVATIVE AND USE THEREOF | 旭化成ファーマ株式会社 (JP) | 2010-04-08 | — | — | WO | disclosed |
| EP-2155706-A2 | REPAGLINIDE SUBSTANTIALLY FREE OF DIMER IMPURITY | Actavis Group PTC EHF (IS) | 2010-02-24 | — | — | EP | disclosed |
| EP-2121644-A2 | IMPROVED PROCESS FOR PREPARING ETHYL (S)-2-ETHOXY-4-[N-[1-(2- PIPERIDINOPHENYL)-3-METHYL-1-BUTYL]AMINOCARBONYL METHYL]BENZOATE AND USE THEREOF FOR THE PREPARATION OF REPAGLINIDE | Actavis Group PTC EHF (IS) | 2009-11-25 | — | — | EP | disclosed |
| WO-2009004485-A2 | REPAGLINIDE SUBSTANTIALLY FREE OF DIMER IMPURITY | ACTAVIS GROUP PTC EHF (IS) | 2009-01-08 | — | — | WO | disclosed |
| US-20080200684-A1 | Process for Preparing Ethyl (s)-2-Ethoxy-4-[N-[1-(2-Piperidinophenyl)-3-Methyl-1-Butyl]Aminocarbonyl Methyl]Benzoate and Use Thereof for the Preparation of Repaglinide | ACTAVIS GROUP PTC HF (IS) | 2008-08-21 | — | — | US | disclosed |
| WO-2008099286-A2 | IMPROVED PROCESS FOR PREPARING ETHYL (S)-2-ETHOXY-4-[N-[1-(2- PIPERIDINOPHENYL)-3-METHYL-1-BUTYL]AMINOCARBONYL METHYL]BENZOATE AND USE THEREOF FOR THE PREPARATION OF REPAGLINIDE | ACTAVIS GROUP PTC EHF (US) | 2008-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197732-A1 | Repaglinide Substantially Free of Dimer Impurity | EMG1, DAP3, DRD4 | CHRNB2 2093/4885CHRNA4 1035/4885CHRNB4 2087/4885 |
| US-20250034128-A1 | BCL-XL INHIBITORS | BCL2, BCL2L1, BCL2L10 | CHRNB2 4832/4885CHRNA4 4865/4885CHRNB4 4842/4885 |
| US-20120065404-A1 | Process for Preparing Ethyl (s)-2-Ethoxy-4-[N-[1-(2-Piperidinophenyl)-3-Methyl-1-Butyl]Aminocarbonyl Methyl]Benzoate and Use Thereof for the Preparation of Repaglinide | MEP1B, GABRE, BPGM | CHRNB2 1816/4885CHRNA4 1186/4885CHRNB4 1499/4885 |
| US-20080200684-A1 | Process for Preparing Ethyl (s)-2-Ethoxy-4-[N-[1-(2-Piperidinophenyl)-3-Methyl-1-Butyl]Aminocarbonyl Methyl]Benzoate and Use Thereof for the Preparation of Repaglinide | MEP1B, GABRE, BPGM | CHRNB2 1816/4885CHRNA4 1186/4885CHRNB4 1499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.